Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 651, pseudogene (RNU6-651P) is annotated as a *pseudogene* related to the U6 small nuclear RNA family, which are normally components of the spliceosome essential for pre-mRNA splicing[4]. As a pseudogene, RNU6-651P carries sequence similarity to functional U6 small nuclear RNA genes but contains mutations or structural features that preclude its normal function in splicing. Sequence homology and genomic context indicate that it may produce non-coding transcripts, and, consistent with general pseudogene biology, such sequences can occasionally act as regulators at the RNA level, including acting as competing endogenous RNAs or affecting local chromatin structure, though no functional information exists for this particular gene[3][2][4]. There are no drugs, mechanisms of action, or clinical biomarker roles described for RNU6-651P.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 651, pseudogene (RNU6-651P).